Stockwatch: An oasis of lipid-lowering therapies and a desert of reimbursement
This article was originally published in Scrip
Last week was chock-full of commentary from the FDA Advisory Panels on the new lipid-lowering drugs directed against PCSK9 from Amgen and Sanofi/Regeneron Pharmaceuticals. Amongst those and other related companies, the only share price winner of the week was Sanofi, with its main listing outside of the US, and even then it was for the wrong reason.
You may also be interested in...
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.
Gene and cellular therapies that can replace decades of expensive therapy do not come cheap. Even the initial remedy of payment by installments could be irrelevant when not all patients respond in the same way.
With Lilly, Pfizer and Novartis duking it out for early-stage breast cancer patients, how many drugs for the same indication is too many?